These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 17998507

  • 1. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.
    Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, MARINA Study Group.
    Arch Ophthalmol; 2007 Nov; 125(11):1460-9. PubMed ID: 17998507
    [Abstract] [Full Text] [Related]

  • 2. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
    Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group.
    Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
    [Abstract] [Full Text] [Related]

  • 3. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
    Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM.
    Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
    [Abstract] [Full Text] [Related]

  • 4. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group.
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [Abstract] [Full Text] [Related]

  • 5. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR.
    Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, Ianchulev T, MARINA and ANCHOR Research Groups.
    Ophthalmology; 2010 Apr; 117(4):747-56.e4. PubMed ID: 20189654
    [Abstract] [Full Text] [Related]

  • 6. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.
    Abraham P, Yue H, Wilson L.
    Am J Ophthalmol; 2010 Sep; 150(3):315-324.e1. PubMed ID: 20598667
    [Abstract] [Full Text] [Related]

  • 7. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, Wang EC, Heier J, Kaiser P, Chong V, Korobelnik JF.
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [Abstract] [Full Text] [Related]

  • 8. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
    Mitchell P, Bressler N, Tolley K, Gallagher M, Petrillo J, Ferreira A, Wood R, Bandello F, RESTORE Study Group.
    JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
    Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N.
    Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
    [Abstract] [Full Text] [Related]

  • 10. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.
    Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019
    [Abstract] [Full Text] [Related]

  • 11. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [Abstract] [Full Text] [Related]

  • 12. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials.
    Varma R, Bressler NM, Suñer I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG, BRAVO and CRUISE Study Groups.
    Ophthalmology; 2012 Oct; 119(10):2108-18. PubMed ID: 22817833
    [Abstract] [Full Text] [Related]

  • 13. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG.
    Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
    [Abstract] [Full Text] [Related]

  • 14. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
    Bressler NM, Chang TS, Varma R, Suñer I, Lee P, Dolan CM, Ward J, Ianchulev T, Fine J.
    Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
    [Abstract] [Full Text] [Related]

  • 15. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
    Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N.
    Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
    [Abstract] [Full Text] [Related]

  • 16. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 17. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.